Logo
x

Search

Subscribe Now

Organon

Organon and Shanghai Henlius Biotech Provides Update on P-III Trial of HLX11 (Biosimilar, Perjeta)

Organon and Shanghai Henlius Biotech Provides Update on P-III Trial of HLX11 (Biosimilar, Perjeta)

  • September 30, 2024
Organon to Acquire Dermavant for an Aggregate of ~$1.2B

Organon to Acquire Dermavant for an Aggregate of ~$1.2B

  • September 18, 2024
Organon and Samsung Bioepis Launch Hadlima (biosimilar, adalimumab)

Organon and Samsung Bioepis Launch Hadlima (biosimilar, adalimumab)

  • July 3, 2023
Organon Launches Ontruzant (biosimilar, trastuzumab) for the Treatment of Gastric Cancer

Organon Launches Ontruzant (biosimilar, trastuzumab) for the Treatment of Gastric Cancer

  • November 14, 2022
Organon Entered into a Research Collaboration and Exclusive License Agreement with Cirqle Biomedical for Non-hormonal Contraceptive Therapy

Organon Entered into a Research Collaboration and Exclusive License Agreement with Cirqle Biomedical for Non-hormonal Contraceptiv...

  • July 28, 2022
Organon Entered into an Agreement with Henlius to Commercialize Perjeta (pertuzumab) and Prolia/Xgeva (denosumab) Biosimilars

Organon Entered into an Agreement with Henlius to Commercialize Perjeta (pertuzumab) and Prolia/Xgeva (denosumab) Biosimilars

  • June 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.